Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and neoadjuvant treatments have enhanced ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.